1 / 8

Incidence of CNV in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT)

This study examines the cumulative incidence of choroidal neovascularization (CNV) in the fellow eye in the CATT trial for age-related macular degeneration treatments. It analyzes risk factors, genotype associations, and drug efficacy.

ltorgerson
Download Presentation

Incidence of CNV in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Incidence of CNV in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF for the CATT Research Team Available through http://www.med.upenn.edu/cpob/publications_main.shtml Supported by Cooperative Agreements from the National Eye Institute, National Institutes of Health, DHHS 1

  2. Cumulative Incidence of CNV Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23

  3. Risk Factors for Incidence of CNV in the Fellow Eye from the Cox Proportional Hazards Model - = Characteristic not included in the model; rate ratio and P value not applicable; AREDS = Age-Related Eye Disease Study; PRN = pro re nata; RPE = retinal pigment epithelium. ∗ P value for test of linear trend for age, AREDS risk score, and RPE elevation. † No. and percentage based on the original dosing assignment; hazard ratio, confidence interval, and P value based on dosing regimen as a time-dependent covariate in the model. ‡ Antioxidants: beta carotene, vitamin C, and vitamin E. Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23

  4. Association of CNV in Fellow Eye with Genotype for 4 Single Nucleotide Polymorphisms associated with AMD • * The risk alleles are C for CFH, T for ARMS2, A for HTRA1, and G for C3. • † Cox model with genotype coded according to the number of risk alleles. • ‡ Cox model adjusted for age, gender and smoking status. Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23

  5. 2-Year Incidence of CNV by Drug P=0.17 (n=365) (n=362) Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23 5

  6. 2-Year Incidence of CNV by AREDS Risk Score for the Fellow Eye P=0.004 Both (n=37) (n=111) (n=552) Large Drusen and Pigmentary Changes Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23 6

  7. 2-Year Incidence of CNV by Gender P=0.004 (n=446) (n=281) Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23 7

  8. Summary • In year 1, nearly equal incidence with ranibizumab and bevacizumab • By 2 years, 4% less with ranibizumab , 20% reduction, but not statistically significant (p≈ 0.20) • Intriguing… • VEGF serum levels in humans suppressed more with bevacizumab than ranibizumab (IVAN, 2012; N=610) • Animals- fellow eye effects for bevacizumab only: vitreous, subretinal NV • CATT data not sufficient to distinguish random variability from true systemic effect Maguire et al. Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology Epub 2013 May 23

More Related